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Abstract CTCF is a transcriptional repressor of the c-myc
gene. Although CTCF has been characterized in some detail,
there is very little information about the regulation of CTCF
activity. Therefore we investigated CTCF expression and
phosphorylation during induced differentiation of human myeloid
leukemia cells. We found that: (i) both CTCF mRNA and
protein are down-regulated during terminal differentiation in
most cell lines tested; (ii) CTCF down-regulation is retarded and
less pronounced than that of c-myc ; (iii) CTCF protein is
differentially phosphorylated and the phosphorylation profiles
depend on the differentiation pathway. We concluded that CTCF
expression and activity is controlled at transcriptional and post-
transcriptional levels.
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1. Introduction
c-Myc is a transcription factor of the helix-loop-helix/leu-
cine zipper family involved in the regulation of proliferation,
di¡erentiation and apoptosis in many di¡erent cell types (re-
viewed in [1,2]). Myeloid leukemia cell lines have been very
useful models in elucidating molecular mechanisms of c-Myc
function. Studies on these cells have established that: (i) in cell
lines such as HL60, U937, HEL and K562, c-myc expression
is dramatically down-regulated during the induced di¡erentia-
tion into several phenotypes [3^6], (ii) c-myc ectopic expres-
sion inhibits erythroid di¡erentiation of murine F-MEL [7] or
human K562 cells [8], and monocytic di¡erentiation of U937
cells [4], (iii) c-myc inhibition by antisense oligonucleotides in
HL60 [9] or overexpression of myc inhibitory mutants or max
in K562 [10] induces myeloid cell di¡erentiation. However,
less progress has been made in de¢ning the mechanisms reg-
ulating the expression of c-myc itself in general, and transcrip-
tion factors involved in c-myc regulation in particular. The
extensive and complex regulation of c-Myc expression has
led to the identi¢cation of a number of factors which regulate
its expression upon binding to speci¢c sequences within the 5P
regulatory regions. Most of them are positive transactivators
(reviewed in [11]), but transcriptional repressors of c-Myc
have also been described [12,13]. We had previously discov-
ered and characterized one of the factors involved in the reg-
ulation of c-myc, the CTCF protein.
CTCF was ¢rst identi¢ed as the protein interacting with
three repeats of the CCCTC motif in the chicken c-myc pro-
moter [14]. The CTCF gene encodes an 11-zinc ¢nger protein,
it is ubiquitously expressed and highly conserved [15,16]. In-
terestingly, di¡erent zinc ¢ngers are involved in the binding of
chicken or human c-myc promoters, thus classifying CTCF as
a ‘multivalent’ transcriptional factor with multiple sequence
speci¢city [16]. CTCF binds to a negative element upstream
of the chicken c-myc promoter and to several sites in the
promoter and coding regions of the mouse and human c-
myc genes [15,16]. CTCF has been shown to negatively regu-
late the expression of the c-myc gene [16], the chicken lyso-
zyme gene [17] but to positively regulate the amyloid-L protein
precursor promoter [18]. It has been found that the human
CTCF gene is localized at the chromosome 16q22.1 locus, a
region commonly deleted in breast and prostate cancers [19].
These data suggest that CTCF is a tumor suppressor gene.
Despite the fact that many of the structural and functional
properties of CTCF have been described, much less is known
about regulation of CTCF expression. This is particularly
important since CTCF is a ubiquitous factor, found in all
tissues and cell lines analyzed so far [19]. In order to gain
insight into how CTCF expression is modulated, we studied
CTCF mRNA and protein levels as well as CTCF protein
phosphorylation during myeloid cell di¡erentiation. We used
several human leukemia cell lines arrested at di¡erent stages
of di¡erentiation and determined CTCF expression and phos-
phorylation state during the chemically induced di¡erentia-
tion. We compared CTCF and c-myc expression and found
di¡erential expression and phosphorylation of CTCF, which
was dependent on the cells’ di¡erentiation pathways.
2. Materials and methods
2.1. Cells and induction of di¡erentiation
Human cell lines NB4, Raji, CA46, Manca and Daudi were kindly
donated by S. Collins (Fred Hutchinson Cancer Research Center,
Seattle, WA, USA). The other leukemia cell lines were obtained
from ATCC. Cells were cultured in RPMI 1640 medium supple-
mented with 10% fetal calf serum and antibiotics. Exponentially grow-
ing K562 cells were induced to di¡erentiate with 1 WM 1-L-D-arabi-
nofuranosylcytosine (ara-C), 10 nM 12-O-tetradecanoyl phorbol-13-
acetate (TPA) or 100 nM staurosporine (STA). HL60 cells were ex-
posed to 1.2% dimethyl sulfoxide (DMSO), 1035 M all-trans-retinoic
acid (RA) or 16 nM TPA. U937 and THP1 cells were treated with 20
nM TPA. Cell morphology was determined by Giemsa staining. The
erythroid di¡erentiation was assessed with the benzidine cytochemical
test and O-globin gene expression [8]. Monocytic and granulocytic
di¡erentiation was assessed by standard morphological criteria. Cell
clustering activity, adherence to surface and induction of the vimentin
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gene [20] were also used as markers of monocytic di¡erentiation. The
di¡erentiation towards monocytic versus granulocytic lineages was
assessed by staining for the K-naphthyl acetate esterases (monocytic
esterases) and for the chloroacetate esterases (neutrophil esterases).
2.2. RNA preparation and Northern blot analysis
For RNA analysis, total RNAs were prepared by the guanidine-
thiocyanate method [21], separated by electrophoresis through agar-
ose-formaldehyde gel and transferred to nitrocellulose. Filters
were hybridized sequentially to the di¡erent probes labeled with
[K-32P]dCTP by random priming. Semiquantitative determination of
mRNA levels was carried out by measuring the radioactivity of the
¢lters with a Molecular Imager apparatus (Bio-Rad). Probes for hu-
man c-myc, O-globin and vimentin were as described [8]. For human
CTCF, a 2 kb PvuII cDNA fragment from pCI7.1 CTCF [16] was
used.
2.3. Western blot assay
For immunodetection of CTCF, cell pellets were lysed in a bu¡er
containing 100 mM Tris (pH 6.8), 8% L-mercaptoethanol, 4% SDS
and 20% glycerine. Protein content was measured using the Bio-Rad
Protein Assay. 30 Wg of protein per lane was separated in 8% acryl-
amide gels and transferred to nitrocellulose. Equal protein loading
was assessed by Coomassie blue staining of the gels after transfer.
CTCF protein was detected by a rabbit anti-CTCF polyclonal anti-
body kindly donated by V. Lobanenkov (Fred Hutchinson Cancer
Research Center, Seattle, WA, USA). Immune complexes were re-
vealed by chemiluminescence (ECL, Amersham, UK).
2.4. Isoelectric focusing (IEF) assay
Cells (5U106) were collected and lysed in a standard 0.5 M salt
RIPA bu¡er. The cell lysates were then spun to remove DNA and the
proteins in the supernatants were precipitated with acetone. After
drying, the proteins were resolved in the sample bu¡er containing
6 M urea, 5% CHAPS, 1% ampholyte pH 4^6, 50 mM NaF and
2% L-mercaptoethanol, in a volume which gives the equivalent of
0.5U105 cells in 20 Wl sample bu¡er. IEF was performed on a hori-
zontal system (Pharmacia) using precast IEF gel on a glass plate with
pH range 4^6. The IEF gel contained 5% acrylamide, 10% v/v sorbi-
tol, 1% CHAPS and 2% ampholyte (Fluka). The electrode bu¡ers
were 0.1 M L-alanine and 0.1 M glutamic acid in 0.5 M H3PO4 for
the cathode and anode, respectively. The electrophoresis was per-
formed at 2000 V and 10 mA at 10‡C during 2.5 h. Immediately after
the electrophoresis was completed, the gel was soaked in the bu¡er
containing Tris base 10 mM, 0.5% SDS, 20% methanol for 30 min
and proteins were transferred onto PVDF membranes using a semidry
transfer system. After blocking in 1% BSA and 1% PVP, the mem-
brane was ¢rst probed with the anti-CTCF antibodies and then with
the secondary anti-rabbit IgG peroxidase-conjugated antibodies. The
bands were visualized by ECL.
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Fig. 1. Expression of CTCF and c-myc in hematopoietic cell lines.
Total RNA was isolated from exponentially growing cells of the in-
dicated cell lines and analyzed by Northern blot. The same mem-
brane was consecutively hybridized to the CTCF and c-myc probes.
A picture of the ¢lter after transfer is shown to assess the loading
and integrity of the RNAs.
Fig. 2. Expression of CTCF and c-myc in K562 cells treated with ara-C, TPA or STA. Exponentially growing K562 cells were exposed to 1 WM
ara-C, 10 nM TPA or 100 nM STA for up to 5 days. Lane 0 shows control cells prior to drug addition. Total RNAs were isolated and ana-
lyzed by Northern blot. The ¢lters were consecutively hybridized to the indicated probes. The experiments were performed at least twice and
similar results were obtained. Graphs at the bottom represent the quanti¢cation of the Northern blots. Relative expression levels were deter-
mined by measuring the CTCF and c-myc signals, as described in Section 2, and the values normalized with respect to 28S rRNA.
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2.5. Two-dimensional IEF
The IEF was performed on precast 2D-IEF gel strips on a plastic
¢lm support. The gel was composed of 5% acrylamide, 6 M urea, 5%
glycerol, and 2.2% carrier ampholyte pH 3.5^10. 0.5 M NaOH and
0.15 M H3PO4 were used for the cathode and the anode, respectively.
The electrophoresis was run on the horizontal system (Pharmacia) at
a maximum of 1500 V and 10 mA at 10‡C during 3 h. After the
electrophoresis was complete, the strips were soaked in SDS-PAGE
standard sample bu¡er and further applied to 10% SDS-PAGE. The
proteins resolved in SDS-PAGE were transferred onto PVDF mem-
branes by semidry transfer. The ¢lter was probed with the rabbit anti-
CTCF antibodies as described above.
3. Results
CTCF is present in a wide range of tissues [19]. We have
further investigated CTCF expression in a variety of cell lines
derived from chronic myeloid leukemia in blastic crisis (K562,
KU812, KBM5 and MEG01), acute myeloid leukemia (HEL,
HL60, U937, THP1 and NB4) or Burkitt lymphomas (Raji,
CA46, Manca and Daudi). As shown in Fig. 1, CTCF mRNA
with an approximate size of 4 kb is expressed in all cell lines.
We did not observe major di¡erences in CTCF mRNA ex-
pression among cell lines from di¡erent leukemic origins. The
same blot was re-hybridized to a human c-myc probe to com-
pare the expression of CTCF with that of its target gene, c-
myc. There are small di¡erences in the ratio CTCF/c-myc
among the di¡erent cell lines (Fig. 1). Thus the NB4 promye-
locytic cell line shows the lowest ratio while the Raji Burkitt
lymphoma cell line has the highest ratio. To further analyze
the regulation of CTCF during myeloid di¡erentiation, we
chose four of these lines representing di¡erent stages of mye-
loid di¡erentiation: K562, HL60, U937 and THP1.
The K562 cell line represents immature hemopoietic precur-
sors that express erythroid markers. Cells can be di¡erentiated
into the erythroid lineage by incubation with ara-C [22,23] or
into the monocytic/macrophagic lineage by phorbol esters, i.e.
TPA (in these cultures, cells express both megakaryocytic and
monocytic markers [23,24]). We have recently described that
the PKC inhibitor STA induces megakaryocytic di¡erentia-
tion of K562 cells (Lerga et al., submitted). Exponentially
growing K562 cells were exposed to these three agents and
cell proliferation and e¡ectiveness of di¡erentiation were
monitored for up to 5 days after the addition of the inducing
agents. Treatment with ara-C induced cell growth arrest, in-
creased the O-globin expression (Fig. 2, left) as well as the
fraction of benzidine positive, i.e. hemoglobinized, cells
(data not shown). Treatment of K562 cells with TPA led to
the appearance of cells with speci¢c monocyte features: ability
for latex phagocytosis, adherence to the surface, formation of
cell clusters (data not shown) and vimentin mRNA up-regu-
lation (Fig. 2, center). On the other hand, the TPA di¡eren-
tiated cells lost the expression of erythroid markers such as O-
globin (not shown). Treatment of K562 cells with STA re-
sulted in the appearance of cells with megakaryocytic features
such as increased cell size, appearance of multinucleated cells,
loss of O-globin expression (not shown) and increased vimen-
tin expression (Fig. 2, right).
To investigate expression of CTCF and c-myc, total RNA
was isolated from K562 cells, electrophoretically separated,
blotted to ¢lters and hybridized sequentially with 32P-labeled
probes speci¢c for human CTCF and c-myc. We found that
the CTCF mRNA decreased during the erythroid di¡erentia-
tion, in parallel with the down-regulation of c-myc expression
(Fig. 2, left). Quanti¢cation of CTCF and c-myc signals
showed about three-fold reduction of expression of both genes
after 5 days of exposure to ara-C, as shown in the graph (Fig.
2, left). Similar down-regulation of CTCF mRNA (2.5-fold)
was found in K562 cells after induction of monocytic di¡er-
entiation by TPA (Fig. 2, center). However, the decrease of c-
myc expression with TPA was faster and more pronounced
(about 10-fold), thus con¢rming previously published obser-
vations [5]. Comparable results were obtained when K562
cells were induced with STA towards the megakaryocytic
pathway (Fig. 2, right) : a strong and rapid down-regulation
of c-myc expression (10-fold) and a gradual decrease in CTCF
expression (three-fold).
As has been previously reported, CTCF migrates as a 130
kDa protein on SDS-PAGE [25]. We found a decrease of the
CTCF protein during the erythroid, monocytic and megakar-
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Fig. 3. Analysis of CTCF protein expression and phosphorylation
in K562 cells. A: Immunoblot of CTCF protein in cells treated
with ara-C, TPA and STA, as described in Fig. 2, for the indicated
periods of time. The positions of molecular mass markers are indi-
cated on the left. B: Isoelectric focusing assay of the CTCF protein
in K562 cells. Cell extracts were prepared from the cells treated for
up to 3 days with the three inducers and the IEF assay was con-
ducted as described in Section 2. The positions of di¡erentially
phosphorylated forms of CTCF are shown on the right (from ‘a’ to
‘d’). The positions of the anode (‘+’) and cathode (‘3’) are shown
on the left. Lane 0 refers to untreated control cells. C: Two-dimen-
sional IEF assays of CTCF in untreated K562 cells (top panel) and
cells after 3 days of exposure to ara-C (bottom panel). The position
of a CTCF protein of 130 kDa is shown on the right and the di¡er-
entially phosphorylated forms of CTCF are indicated by arrows.
M.D. Delgado et al./FEBS Letters 444 (1999) 5^10 7
yocytic di¡erentiation of K562 cells, as judged by Western
blot analyses of cells treated with the speci¢c inducers for
up to 5 days (Fig. 3A). The decrease in CTCF protein levels
is consistent with the mRNA down-regulation observed in
Fig. 2. We also investigated whether di¡erentiation of K562
provoked changes in the phosphorylation state of CTCF. We
performed IEF assays at treatment times where CTCF protein
is still present. As shown in Fig. 3B, the IEF reveals that
CTCF protein is represented by several forms: the hypophos-
phorylated closely migrating forms ‘a’ and ‘b’, isofocused near
the anode, the intermediately phosphorylated form ‘c’, and
the hyperphosphorylated form ‘d’ isofocused near the cath-
ode. In undi¡erentiated cells CTCF is in the hypophosphoryl-
ated form (Fig. 3B, day 0). No signi¢cant changes were ob-
served in the phosphorylated state of CTCF upon induction
with TPA and STA, where CTCF remains hypophosphoryl-
ated. However, erythroid di¡erentiation of K562 provoked
the appearance of two higher phosphorylated forms (‘c’ and
‘d’ forms). To con¢rm that all these forms are speci¢c and
correspond to the modi¢ed forms of CTCF, we performed a
two-dimensional IEF assay. When resolved in the second di-
mension all proteins detected with the anti-CTCF antibody
migrated as 130 kDa proteins (Fig. 3C, top panel, K562
non-induced; Fig. 3C, bottom panel, K562 cells induced
with ara-C for 3 days).
Next we studied the CTCF regulation in HL60, a more
di¡erentiated myeloid cell line with bipotential capability of
di¡erentiation towards granulocytic or monocytic lineages (re-
viewed in [3]). Treatment of HL60 cell with DMSO or retinoic
acid up to 5 days induced granulocytic features as assessed by
morphological and cytochemical analysis (see Section 2). As
shown in Fig. 4, left, CTCF mRNA levels remained elevated
1 day after DMSO treatment, decreasing thereafter (three-fold
after 5 days). The RA treatment also led to down-regulation
of CTCF mRNA after 2 days (Fig. 4, center). To con¢rm the
observed CTCF down-regulation during the granulocytic dif-
ferentiation process, we used the murine cell line 32-D Cl3
[26]. These cells are non-tumorigenic, IL-3 dependent, and
can be induced to granulocytic di¡erentiation with granulo-
cyte colony stimulating factor (G-CSF). We found that the
130 kDa CTCF protein was also down-regulated in this mur-
ine cell line after 3 days of treatment with G-CSF (results not
shown).
When HL60 cells were exposed to TPA, the monocytic
phenotype was clearly induced as assessed by cell morphol-
ogy, increased adherence to surface and the induction of vi-
mentin gene expression (Fig. 4, right). In this case, a progres-
sive decrease in CTCF expression was also observed (2.5-fold
after 5 days). A strong down-regulation of c-myc (10^15-fold)
was detected after di¡erentiation of HL60 cells with all three
agents, in agreement with published observations [3,6]. West-
ern blot analysis of the lysates from HL60 cells treated with
TPA and DMSO (Fig. 5A) revealed that the levels of CTCF
protein progressively decreased after induction of cell di¡er-
entiation towards the monocytic (with TPA) or granulocytic
(with DMSO) pathways, although CTCF suppression was
more pronounced after TPA treatment. Analysis of the phos-
phorylation pro¢le of the CTCF protein in HL60 cells upon
induction of monocytic and granulocytic pathways demon-
strated that, in contrast to K562, all four CTCF forms (‘a’,
‘b’, ‘c’ and ‘d’) were present in HL60 non-di¡erentiated cells.
After treatment with TPA, only hypophosphorylated forms of
CTCF (‘a’ and ‘b’) were observed, and form ‘c’ (intermediate)
disappeared after treatment with DMSO (Fig. 5B).
U937 and THP1 are more mature monoblastic cell lines
with the capacity to di¡erentiate only towards the mono-
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Fig. 4. Expression of CTCF and c-myc in HL60 cells treated with DMSO, RA or TPA. Exponentially growing HL60 cells were exposed to
1.2% DMSO, 1035 M RA, or 16 nM TPA for the indicated times. Total RNAs were isolated and analyzed by Northern blot as described in
Fig. 2. Graphs at the bottom represent the quanti¢cation of the Northern blots.
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cytic/macrophagic lineage by treatment with TPA [4,6,27].
This phenotype was con¢rmed by the appearance of several
monocytic morphological characteristics described above
(data not shown) and also by the increase of vimentin
mRNA expression (Fig. 6). Upon cell di¡erentiation of these
two cell lines, the CTCF mRNA levels were only reduced
around 2^2.5-fold, while the c-myc expression decreased dra-
matically. In particular, c-myc mRNA levels in U937 cells
were almost undetectable 12 h after TPA addition, while the
CTCF mRNA levels remained elevated. Consistently, the
CTCF protein contents were found to be only slightly de-
creased after 5 days of TPA treatment in both cell lines
(Fig. 7A).
Despite the absence of apparent di¡erences between the
CTCF protein levels in THP1 and U937 upon cell di¡erentia-
tion, the phosphorylation of CTCF changed dramatically.
Thus, the positions of the CTCF forms in these cells di¡ered
from HL60 and K562, therefore they were called ‘e’, ‘f’, ‘g’
and ‘h’. An intermediate form ‘f’ is characteristic for non-
induced U937 cells, whilst the hypophosphorylated form ‘e’
in addition to hyperphosphorylated forms ‘g’ and ‘h’ was seen
in the induced cells (Fig. 7B, lanes 1^3). In non-induced THP1
cells two bands ‘g’ and ‘f’ could be detected, which disap-
peared upon induction with TPA. However, the presence of
a strong band corresponding to form ‘h’ was seen 1 day after
TPA addition (Fig. 7B, lanes 4^6).
4. Discussion
In this study we have investigated di¡erential expression
and phosphorylation of CTCF during di¡erentiation of four
leukemia cell lines into erythroid, megakaryocyte, granulocyte
and monocyte-like cells. Three general conclusions could
be drawn from this study: (i) both mRNA and protein
CTCF are generally down-regulated during di¡erentiation
into the di¡erent phenotypes, although there are marked dif-
ferences depending on the cell line and di¡erentiation path-
way; (ii) CTCF down-regulation is delayed and less pro-
nounced than that of c-myc ; (iii) there is a di¡erential
phosphorylation of CTCF protein which depends on the cell
line and di¡erentiation pathway.
It is noteworthy that the decrease in CTCF protein is de-
tected only once the di¡erentiation process has become irre-
versible, i.e. the cells are committed to terminal di¡erentia-
tion. In K562 this commitment requires 24, 12 and 2 h of
ara-C, staurosporine and TPA treatment, respectively ([5]
and Lerga et al., submitted). In most cases, down-regulation
of c-Myc precedes that of CTCF, in full agreement with the
described negative e¡ect of CTCF on c-myc promoter activity
[16]. There are noticeable di¡erences between the CTCF and
c-Myc expression pro¢les among the di¡erent cell lines in-
duced into the monocytic pathway (K562, HL60, U937 and
THP1 treated with TPA). These di¡erences may re£ect the
di¡erent stages of maturation of these cell lines. For example,
CTCF protein down-regulation is much smaller and slower in
U937 and THP1 cells, which may re£ect the fact that both cell
lines are unipotent (promonocytic) and more mature than
K562 or HL60.
We have recently demonstrated that CTCF is a phospho-
protein and is phosphorylated in vivo in COS6 cells by casein
kinase II (Klenova et al., in preparation). It is conceivable
that the phosphorylation pattern of CTCF depends on the
cell type, particular inducers or cell state (i.e. whether it is
di¡erentiated or cycling). Our present study shows that
CTCF has a speci¢c phosphorylation pro¢le in di¡erent cell
types, thus implying that other protein kinases may be in-
volved in CTCF phosphorylation. Furthermore, the phos-
phorylation pattern of CTCF changes upon terminal di¡er-
entiation, therefore suggesting a functional importance of
CTCF phosphorylation in the cells. In most cases CTCF is
under- or de-phosphorylated in proliferating cells, but higher
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Fig. 5. Analysis of CTCF protein expression and phosphorylation
in HL60 cells. A: Immunoblot of CTCF protein in HL60 cells
treated with TPA or DMSO, for the indicated periods of time. The
positions of molecular mass markers are indicated on the left. B:
IEF assay of the CTCF protein in HL60 cells. Cell extracts were
prepared from the cells treated with TPA and DMSO (days after
treatment are indicated). The positions of di¡erentially phosphoryl-
ated forms of CTCF (‘a’ to ‘d’) are shown on the right and the
anode (+) and cathode (3) positions on the left. Lane 0 refers to
untreated cells.
Fig. 6. Expression of CTCF and c-myc in U937 and THP1 cells
treated with TPA. Exponentially growing U937 and THP1 cells
were exposed to 20 nM TPA for the indicated times. Total RNAs
were isolated and analyzed by Northern blot as described in Fig. 2.
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phosphorylated forms can be observed when cells are induced
to di¡erentiate. Since the latter is accompanied by c-myc and,
in most cases, CTCF down-regulation, it is tempting to spec-
ulate that external signals triggering the di¡erentiation pro-
gram also lead to di¡erential phosphorylation of CTCF.
Thus, a particular combination of di¡erently phosphorylated
forms of the CTCF protein may be responsible for regulating
the expression of lineage speci¢c genes, leading to the switch
to di¡erent di¡erentiation programs. We have previously
demonstrated that CTCF acts as a repressor of c-myc [16],
however, our recent studies revealed that CTCF can also neg-
atively auto-regulate its own promoter (Filippova et al., sub-
mitted). Therefore, it is possible that di¡erently modi¢ed
forms of CTCF could speci¢cally regulate the expression of
c-myc and CTCF genes after induction of di¡erentiation.
However, one cannot rule out that other genes, in addition
to CTCF and c-myc, may be targets for regulation by CTCF
in those cells. This possibility is particularly suitable to di¡er-
entiation of U937 and THP1 cells, where there is no correla-
tion between the c-Myc down-regulation and the sustained
levels of the CTCF.
In summary, here we present data showing that during the
di¡erentiation of human myeloid cell lines, the expression of
CTCF and also its phosphorylation pro¢le are di¡erentially
regulated depending on the speci¢c di¡erentiation pathway. In
future studies we will attempt to map the phosphorylation
sites in these cells and investigate their importance in the
regulation of CTCF at the c-myc and CTCF promoters.
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Fig. 7. Analysis of CTCF protein expression and phosphorylation
in U937 and THP1 cells. A: Immunoblot of CTCF protein in cells
treated with 20 nM TPA for up to 5 days. The positions of molecu-
lar mass markers are indicated on the left. B: IEF assay of CTCF
protein in U937 and THP1 cells treated with 20 nM TPA for up to
3 days. The positions of di¡erently phosphorylated CTCF protein
(‘e’ to ‘h’) are shown on the right and the anode (+) and cathode
(3) positions on the left. Lane 0 refers to untreated cells.
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